Oral Treatment Candidate Etrasimod Found to be Safe and Effective for Ulcerative Colitis, Open-label Trial Extension Shows

Oral Treatment Candidate Etrasimod Found to be Safe and Effective for Ulcerative Colitis, Open-label Trial Extension Shows
Arena Pharmaceuticals announced that its investigational oral treatment, Etrasimod, led to long-term clinical response and remission in patients with ulcerative colitis. The candidate treatment was also found to be safe and well-tolerated in an open-label extension of the company's Phase 2 OASIS trial. "We are pleased with the long-term safety and efficacy that Etrasimod has demonstrated in the open-label extension of our Phase 2 OASIS trial," Preston Klassen MD, MHS, Arena's executive vice president of research and development, and Chief Medical Officer, said in a press release. "These data further support our belief in Etrasimod as an important future therapy in inflammatory bowel disease and our strong commitment to improve the lives of patients suffering from these grievous conditions." Ulcerative colitis is a type of inflammatory bowel disease characterized by inflammation and ulceration of the colon, leading to frequent bowel movements, diarrhea, and abdominal cramps. The disease results from an exacerbated immune response, and, therefore, the common treatments are anti-inflammatory medicines and immunosuppressants. Etrasimod works by modulating the selective sphingosine 1 phosphate receptor, which is involved in different biological processes including immune cell recruitment. By modulating the receptor, the treatment reduces the number of immune cells in affected areas, thus diminishing immune response and alleviating symptoms. The 34-week open-label extension of Arena's Phase 2 OASIS trial (NCT02536404) evaluated the long-term safety, tolerability, and efficacy of Etrasimod in 188 subjects with ulcerative colitis, 84% of whom had previously participated in the 12-week randomized OASIS trial (NCT02447302). Of the 118 subjects, 105 received 
Subscribe or to access all post and page content.